INTRODUCTION
The main difference between organ doses calculated for MWDS-2013 and previously calculated organ doses used for further epidemiological calculations (1) (2) (3) is that MWDS-2013 explicitly considers uncertainties within the dose calculations. The calculations involved in MWDS-2013 are, as a consequence, far more complicated and time consuming: taking over a month of CPU computer time to calculate the required doses and their uncertainties for the whole cohort of Mayak workers. In order to be sure that the calculated doses were accurate (i.e. the implementation of the models was correct), a rigorous system of quality assurance (QA) was put in place. The QA was divided into 2 distinct phases. Phase I dealt with the calculations of intakes, bioassay quantities, excretion rates and a single set of dose estimates based on a fixed set of parameter values, and preliminary QA of the methodology developed to incorporate uncertainty into the parameter values and is described in this paper. Phase II was concerned with the QA of the final calculated doses using the agreed uncertainties and is described in an accompanying paper (4) . QA was performed by comparing the results of two separate software codes using identical starting assumptions. The first code, PANDORA, was developed at the Southern Urals Biophysics Institute (SUBI) specifically for MWDS-2013; the second code was developed by Public Health England (PHE) in the UK, and involved extending the capabilities of the software IMBA Professional Plus (5) to deal with the different structure of the MWDS-2013 biokinetic models.
DESCRIPTION OF COMPUTER CODES
The two software codes that existed at the start of the MWDS-2013 project had been developed for entirely different purposes. The SUBI code was written specifically to calculate organ burdens and doses for the Mayak Worker Cohort for previous epidemiological investigations and therefore included intake regimes and biokinetic models specifically tailored to this cohort. IMBA, however, had the much wider remit to allow the calculation of intakes and internal doses to workers exposed to all radioactive material within the framework of recommendations provided by the International Commission on Radiological Protection (ICRP). As such, IMBA implements the latest ICRP dosimetry and models (6) (7) (8) and supports both acute and chronic intake regimes. The SUBI code did not implement ICRP dosimetry and therefore new code (PANDORA) was written. Both PANDORA and, historically, IMBA were written with a large degree of flexibility built in to allow them to efficiently incorporate new models and model structures, and to easily allow the input of new parameter values.
In order to quality assure the calculated doses, the two codes in development for MWDS-2013 analysis (i.e. PANDORA and IMBA) had to converge towards a common set of agreed modelling and dosimetry assumptions based on ongoing results from analysis of the Mayak workers' data sets and pertinent current research findings. As a starting point, the two codes were quality assured by modifying each to incorporate both the DOSES-2005 and MWDS-2008 dosimetry systems. It is written in C++ and is run on a mainframe computer (9) .
IMBA
IMBA Professional Plus is a commercially available software package that estimates both acute and chronic intakes of radionuclides (single and multiple) from measurements of activity in organs and/or excreta and calculates resulting doses using dosimetry recommended by the ICRP. The user interface is written in Visual Basic; this interface uses calculational modules that are written in a variety of languages to optimise speed. It is designed to be run on personal computers. During its development, IMBA underwent extensive QA (10, 11) and within the United States it is formally accredited under the U.S. Department of Energy accreditation system. (12) INITIAL QA Initial QA involved testing the modified codes using the models and dosimetry of DOSES-2005 and MWDS-2008. Two comparisons were carried out: the direct forward calculation of doses from a given intake scenario and the inverse calculation of effective dose starting from bioassay data and involving the calculation of intake as an intermediate step in the quantification of absorbed dose.
For the forward calculations, absorbed dose coefficients for each calendar year from first exposure in 1950 until the year 2000 were calculated independently by the two codes for a typical worker exposure (Case number 8230). Comparisons of doses for the lungs, liver, bone surfaces and red bone marrow (RBM) were carried out for the two plutonium compounds present in Mayak workplaces, nitrates and oxides. The lungs (alveolar interstitium (AI) region of the respiratory tract) were chosen due to the intake occurring by inhalation, while the liver and the skeleton (specifically the RBM and bone surfaces) were selected because they are the systemic organs accruing most of the radioactive plutonium following its absorption from the lungs. The lungs, liver and skeleton were also amongst the organs sampled at autopsy. Three intake regimes were considered for the dose calculations. The first two represented the two extremes of possible intake: an acute inhalation of 1 Bq on Day 1 and a chronic inhalation of 1 Bqd -1 for 50 y. The intermediate case of a chronic inhalation modelled as a decaying exponential intake was also quality assured as this exposure scenario is a more realistic representation of the pattern of exposure over a Mayak worker's lifetime, was used in MWDS-2008 dose calculations and was also identified as a potential intake pattern for reconstruction of doses for MWDS-2013. For the case used for this part of the QA, the exponentially decaying chronic inhalation was modelled as an initial inhalation of 1 Bq on Day 1 with a half-life of approximately 77 y.
The inverse QA calculations (estimating intakes from bioassay data) were based on the scenario of a worker's single 24 h urine sample collected 30 y after first exposure and containing a measured activity of 1 mBq. Both smokers and non-smokers, nitrates, oxides and a mix of nitrates and oxides, for both acute and chronic intakes were considered for the estimates of intakes and absorbed lung and liver dose calculations.
Validation of doses, intakes and bioassay quantities were dependent on comparisons being consistent to 1% or less. Percentage differences between codes were calculated as follows:
where Q is the quantity of interest (e.g. intake, organ burden and absorbed dose).
Development of computer codes for DOSES-2005 and MWDS-2008
The modifications carried out for the QA of the PANDORA software code using (13) • Modification of output to a compatible format for comparison with the IMBA (PHE) output.
IMBA
• Implementation of the Leggett systemic model for plutonium (14) • 
Problems identified and solved
Several inconsistencies between the PANDORA and IMBA codes were observed during this initial phase of the QA program. In particular, it was immediately apparent that the two codes calculated different lung doses. PANDORA calculated an average lung dose while IMBA calculated the ICRP-defined regionally weighted lung dose. While discussions took place to determine the most appropriate lung dose for further use by epidemiologists for risk estimates (13) , IMBA was modified to allow average lung doses to be calculated. However, on comparing average lung doses, it became apparent that each organisation had implemented a different average lung dose within their code. SUBI defined average lung dose as total energy emitted divided by the mass of the lung while PHE had defined average lung dose as the total energy absorbed by the sensitive cells divided by the mass of the lungs. The definition of average lung dose for inclusion in the codes was then standardized to the SUBI definition and the resulting comparisons of average lung dose per calendar year were consistent to 1% between the codes for all intake regimes, and compounds.
A similar problem was identified with the definition of effective dose when the inverse calculations for chronic intakes and effective doses for the lungs and liver were compared. It was observed that the effective doses calculated by IMBA were consistently higher, between 2 and 9% for lung doses and about 8% for liver doses. However, comparisons between the codes for intakes and effective lung and liver doses showed good agreement for an acute inhalation. The cause of the bias in doses for chronic intakes was found to be due to the different interpretation within each code of the dose quantity 'effective dose' following a chronic intake. The PANDORA code calculated effective dose using a 50 y cut-off date, so that intakes received after Day 1 did not include doses calculated to a full 50 y following those intakes (i.e. intakes received in the second year had absorbed doses calculated up to 49 y, etc.), whereas IMBA calculated effective doses using a rolling 50 y period so that intakes received a year after the start of the chronic intake had effective doses calculated for a full 50 y following the intake (i.e. up until Year 51 from the start of the intake). Again, once the definition of effective dose had been standardized to the PANDORA definition of effective dose with a fixed 50 y cut-off date, the bias disappeared and agreement between the codes to within 1% was achieved.
RESULTS
For acute intakes and all liver, bone surface and RBM absorbed doses, the codes agreed to within 1%. The absorbed average lung doses also agreed after a consistent definition of average lung dose was implemented in both codes. For chronic intakes, all lung, liver, bone surface and RBM absorbed doses agreed to within 1% following the standardisation of the definition of effective dose. Thus, validation of PANDORA for direct dose calculations was observed.
QA OF MWDS-2013-INTAKES TO BIOASSAY
The QA calculations were carried out for organ burdens and urinary excretion rates. The organs chosen for comparison calculations of activity burdens were the lung, thoracic lymph nodes, liver and skeleton. Daily urinary excretion rates were calculated and compared because, for plutonium, urinary excretion is an important pathway for reconstruction of a worker's possible intake and dose. All organ burdens and urinary excretion rates were calculated at times of 1, 3, 10, 30, 100 d and yearly to 20 y from the date of intake. As before, both plutonium nitrate and plutonium oxide were considered. The exposure regimes were chosen to be an acute intake of 1 Bq on Day 1 and a chronic intake of 1 Bqd -1 for 20 y. The validation criteria were as previously used for the preliminary QA: all doses, intakes and bioassay quantities calculated had to agree between software codes to within 1%. The percentage difference in calculated quantities between the two codes was calculated as previously defined.
Due to lessons learned in the preliminary round of QA and in order to minimise the potential for any discrepancies between PANDORA and IMBA outputs resulting from dissimilar initial assumptions (models, modelling assumptions and parameter values), each round of QA was accompanied by a document known as the Parameter Passport which detailed all the models and their parameters which had been agreed between PHE and SUBI. This proved especially valuable because during this phase of the QA process, the methodology was constantly evolving, with new models being implemented and parameter values changed.
Code development
The models and changes implemented in both the PANDORA and IMBA computer codes prior to carrying out the QA of intakes to bioassay for MWDS-2013 were based on the new proposals for changes to the current ICRP respiratory tract model and are as follows:
• Simpler representation of the AI region and slower particle transport clearance (15) .
• Simplified representation of the structure of the upper airways.
• Modifications to the extrathoracic (ET) region which included changing the deposition fraction to ET1 and ET2 while keeping the total deposition in the ET region the same; changing the rate constants from ET1 to ET2 and from ET1 to the environment; and increasing the sequestered fraction from the ET region (16) .
Problems identified and solved
On initial comparison of bioassay calculations, discrepancies of slightly greater than 1% between SUBI and PHE bioassay values for liver (1.64%), skeleton (1.61%) and urinary excretion (1.77%) at early times (Day 1) for both acute and chronic intakes were observed. Comparisons of these bioassay quantities at 3 d showed differences of approximately 0.3%, well within the 1% criteria for agreement. This problem therefore indicated a possible discrepancy in the implemented models in the transport of material at very early times. This discrepancy was eventually found to be due to the mathematical implementation of the transfer of material absorbed from the lungs to the systemic tissues. This necessarily involved a dummy mathematical compartment which allowed for the correct ratio of absorbed activity to instantaneously enter the blood or soft tissues. It proved to be a difference in the rates implemented in the codes from this dummy compartment that caused the ; using the smaller value of 10 d -1 resulted in less activity in the liver, skeleton and urine on Day 1. Once these rates were set to identical values between the codes, the bioassay quantities agreed to within the validation criterion. Rates of 3000 d -1 and 7000 d -1 were agreed upon for the final model implementation.
Results
The calculated organ burdens and urinary excretion rates for plutonium nitrate and plutonium oxide from both IMBA and PANDORA and their comparisons are given in Tables 1-8 . Comparisons of all organ burdens and urinary excretion rates were well within the validation criterion of 1%. The maximum percentage difference for an acute inhalation of plutonium nitrate occurred for the liver at 20 y and had a value of 0.38%. For a plutonium nitrate chronic inhalation over 50 y, the liver on Day 1 showed the maximum percentage difference of 0.28%. For both acute and chronic inhalation of plutonium oxide, the liver on Day 1 showed the maximum percentage difference of 0.27% for both intake patterns. Thus, validation of the PANDORA code for calculations of activity in organs and urinary excretion rates was observed.
QA OF MWDS-2013-INTAKES TO DOSE
Absorbed doses to 11 organs (liver, bone surfaces, RBM, gonads, kidneys, urinary bladder (UB) wall, stomach wall (ST), small intestine (SI) wall, upper large intestine (ULI) wall, lower large intestine (LLI) wall, and muscle) were calculated and compared for each calendar year from 1950 to 1999 inclusive. Doses in each calendar year were also calculated for regions of the respiratory tract for comparison; in particular, the AI region, bb region, BB region and the lymphatic system and lymph nodes that drain the thoracic region (LNTH). The absorbed doses were calculated for alpha particle emissions only. The intake was defined as an acute inhalation of 1 Bq on Day 1 or a chronic inhalation of 1 Bqd -1 over the whole time period of 50 y of plutonium-239 in both oxide and nitrate forms.
Code development
The PANDORA code was modified to include the calculation of the ICRP definition of regional weighted lung dose (8) . Since IMBA already included ICRP methodology for dose calculations, no further code modification was required for this part of the QA.
Problems identified and solved
During the QA process, calculated absorbed doses per calendar year to wall organs (ST, SI wall, LLI wall, ULI wall and UB wall), the BB and bb regions of the lung and to bone surfaces did not agree initially to within 1% for both acute and chronic inhalations. For the wall organs and the bb lung region, this discrepancy was found to result from the omission in one code of the component of dose from the organs not specifically included in the systemic model, those known as the rest of body (ROB) or remainder organs. A further compounding factor, the inclusion or exclusion of the contribution to dose of activity in cortical bone marrow, was identified as the major factor contributing to the discrepancies in bone surface dose. The annual absorbed doses to the BB region of the lung, for both acute and chronic inhalations, even with the ROB dose component added still did not agree within the 1% validation criterion. On further investigation it was discovered that inconsistencies existed between codes in applying the modelling methodology, and in particular the K FB parameter-a factor which allows for a different bound fraction in the upper airways (BB and bb) from that in the AI lung region. Once both codes used consistent methodology and included the cortical bone marrow component in the bone surfaces dose, the absorbed doses per calendar year to the wall organs, the BB and bb regions of the lung and the bone surfaces fell within the 1% validation criterion.
Results
Example results of the calculations from intake to absorbed dose per calendar year for an acute inhalation of plutonium nitrate and a chronic inhalation of plutonium oxide are shown in Tables 9 and 10 . The comparison of doses showed that the maximum percentage difference in absorbed doses occurred for the liver in the year 1996 for both acute (0.94%) and chronic (0.65%) exposures to plutonium nitrate. For an acute inhalation of plutonium oxide, the UB wall had the maximum percentage difference of 0.55% in 1960 while for a chronic intake over 50 y, the thoracic lymph nodes showed the maximum difference of 0.92% in the very first year (1950) following the start of the intake.
QA OF MWDS-2013-BIOASSAY TO INTAKE
The QA of intakes estimated from bioassay measurements involved quality assuring the software code that implements the fitting of an intake to the organ burdens and urinary excretion measurements of the Mayak workers. This involved quality assuring the code which deals with the fitting of autopsy data where all measurements were above the limit of detection (LOD) and urinary excretion data which includes some measurements which are recorded as below the LOD. Each step in this process is explained in more detail in the following sections. All intakes were calculated to the reference time of 1 January 1950 and both an acute inhalation of plutonium nitrate and a chronic inhalation for 10 y (i.e. until 1 January 1960) of plutonium oxide were chosen to cover the range of materials present in the Mayak workplace and the two extremes of exposure.
Code development
The PANDORA software was extended with a module to calculate the likelihood function of the total intake by inhalation for a given intake regime from measurement results of plutonium-239 activity in daily urine samples and/or organs. The new module also incorporated statistical analysis code for interpretation of the probability distributions for estimates of intake, activity in organs, tissues and urine, and absorbed doses. In addition, the IMBA algorithm to interpret organ and daily urinary excretion measurements <LOD was also implemented in the PANDORA code.
Autopsy
The first step in the QA of the fitting algorithms and code to estimate intakes from measured activity in body organs or excreta involved calculating separate intakes from each of the four selected autopsied organs: the lungs, thoracic lymph nodes, liver and skeleton. In addition, the simultaneous fitting of measured activity in all four of these organs to a single intake was also quality assured. The activity in the autopsied organs was simulated assuming both an acute intake of 1 Bq and a chronic intake for 30 y at the rate of 1 Bqd -1
. Organ burdens were calculated to a reference date of 1 January 1980, 30 y following the start of the intake. The organ burdens were subjected to uncertainties by increasing the calculated activity in the lungs and liver by 10% and decreasing the activity in the skeleton and thoracic lymph nodes by 10%. For fitting purposes, a 20% relative error on the simulated organ burdens was assumed; this value was chosen to represent the fact that autopsy measurements are reasonably precise when compared to urine measurements.
Results
The results of the QA are shown in Tables 11 and 12 . All intakes are within the 1% criterion with the mean intake comparison showing the largest difference of 0.05% for fitting of the individual skeleton simulated activity measurement for an acute intake of plutonium nitrate. The median intake comparison showed the largest difference when individually fitting the measured thoracic lymph node activity. All the estimated intakes were consistent with the chosen intakes for the scenarios, 1 Bq acute or 1 Bqd -1 chronic. The intake estimates for individual organs were consistent with the engineered increase and decrease in the measured organ burdens with intake estimates 10% larger than the 1 Bq and 1 Bqd -1 scenario intake for those organs whose measured values were increased by 10% (i.e. the lungs and the liver) and 10% smaller for those whose calculated burdens were reduced by 10% (i.e. the skeleton and the thoracic lymph nodes).
Urinary excretion
The Mayak data for urinary excretion rates, unlike that for autopsied organ burdens, contained a large number of measured values that were below the LOD measurements of the detectors. The fitting algorithms were developed to incorporate these <LOD values. Therefore, the QA program had to include simulated bioassay data with measurements <LOD. For an acute intake of plutonium nitrate, three urinary excretion rates which were above the LOD, calculated at 5, 10 and 15 y following exposure, and which were referred to as REAL measurements, and one urinary excretion rate, calculated at 20 y following exposure, which was below the LOD of the measuring system and known as <LOD were simulated. The simulated bioassay data for a chronic inhalation of plutonium oxide over 10 y consisted of three urinary excretion rates which were below the LOD, calculated at 5, 10 and 20 y following exposure, and one urinary excretion rate, calculated at 15 y, which was above the LOD of the measuring system. For QA of the two software codes, a number of comparisons of the calculation of intake were carried out. For the plutonium nitrate exposures, two intake calculations from the four urine measurements allowed full testing of the fitting routines. The first intake was calculated using only the three measurements above the LOD (i.e. those measured at 5, 10 and 15 y following intake). The second intake was calculated using all four urine measurements and was designed to test the proper implementation of the algorithm which fitted a single <LOD value alongside measured activity. For plutonium oxide, one intake was calculated from all four urine measurements which tested the algorithm for fitting of data with multiple urine measurements <LOD and where most of the recorded values were <LOD. This was a situation commonly found in the Mayak urine measurement data. Lognormal uncertainties with a scattering factor of 1.2 were assumed on all urinary excretion rates for fitting purposes.
Results
The results of the QA are shown in Tables 11 and 12 . All the estimated intakes were comparable between the two codes and well within the 1% criterion defined for QA purposes. For the acute inhalation of plutonium nitrate, a difference of 0.08% was seen in the estimated mean intake calculated by the two different computer codes when the three measurements above the detection limit were fitted. When the additional measurement below the detection limit was included, the difference in the estimated mean intake increased very slightly to 0.09%. For the chronic inhalation of plutonium oxide, the difference between the two codes for the estimated mean intake was less than 0.01% based on urine bioassay.
Autopsy and urinary excretion
To complete the Bioassay to Intake QA, both sets of simulated measurement data (i.e. both autopsy and daily urinary excretion) were combined in the fitting process. All autopsy measurements and daily urinary excretion values were as previously used in the QA of the fitting algorithm. Intakes calculated for the plutonium nitrate exposure used the measurements from all four autopsy organs (all REAL) and the four daily urinary excretion measurements consisting of 1 < LOD and 3 REAL values. For plutonium oxide the urine measurement data to be fitted consisted of 3 < LOD and 1 REAL.
Results
The results of the QA are shown in Tables 11 and  12 . The comparison of intakes showed 0.05% difference in the estimated mean intake between the two computer codes for an acute intake of plutonium nitrate and a 0.00002% difference for a chronic intake of plutonium oxide. Both comparisons are well within the 1% criterion for QA purposes.
CONCLUSION
It is clear from the results detailed here that when new dosimetry methodology and computer codes are being implemented, a well thought-out and structured program of QA is fundamental to the process of producing reliable dose estimates. The QA program of work identified the occasional incorrect implementation of a model and the odd discrepancy in the value of a parameter within a model. However, the use of a 'passport' or document which detailed all the models and parameter values assumed (at that time) in the project was exchanged between the two research establishments immediately prior to undertaking each round of the QA; this limited the introduction of such errors. The early QA, looking retrospectively at previous Mayak dosimetry methodology, proved invaluable as it identified, at an early stage, differences in definitions of dose quantities between PHE and SUBI; in particular, different definitions of 'lung dose' and 'effective dose'. It also proved to be an essential first step towards implementing the new uncertainty methods used in the final dose calculations for MWDS-2013. 
